100+ datasets found
  1. Rate of liver cancer diagnoses in the U.S. in 2021, by age

    • statista.com
    Updated Jul 9, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2024). Rate of liver cancer diagnoses in the U.S. in 2021, by age [Dataset]. https://www.statista.com/statistics/951914/new-liver-cancer-cases-rate-by-age/
    Explore at:
    Dataset updated
    Jul 9, 2024
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    2021
    Area covered
    United States
    Description

    The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

  2. Liver cancer cases in England 2021, by age and gender

    • statista.com
    Updated Jul 11, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Liver cancer cases in England 2021, by age and gender [Dataset]. https://www.statista.com/statistics/1034842/liver-cancer-cases-england-age/
    Explore at:
    Dataset updated
    Jul 11, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    2021
    Area covered
    United Kingdom (England)
    Description

    In 2021, there were over *** thousand registrations of newly diagnosed liver cancer in England. With a total of *** cases in this year, the age group most affected by liver cancer in terms of number of cases was that of 70 to 74 year old men. It should of course be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to liver cancer.

  3. S

    Primary Liver Cancer CECT Imaging Dataset

    • scidb.cn
    Updated Aug 25, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Jiawei Luo; Shixin Huang; Xixi Nie; Xiaoyu Wan (2024). Primary Liver Cancer CECT Imaging Dataset [Dataset]. http://doi.org/10.57760/sciencedb.12207
    Explore at:
    CroissantCroissant is a format for machine-learning datasets. Learn more about this at mlcommons.org/croissant.
    Dataset updated
    Aug 25, 2024
    Dataset provided by
    Science Data Bank
    Authors
    Jiawei Luo; Shixin Huang; Xixi Nie; Xiaoyu Wan
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Primary liver cancer is a significant global health issue, characterized by high incidence and mortality rates worldwide. Accurate diagnosis and classification of subtypes are essential for selecting appropriate treatment options and enhancing patient outcomes. Contrast-enhanced computed tomography (CECT) has proven highly sensitive and specific in diagnosing liver cancer. Currently, publicly available datasets of liver cancer CECT scans are limited and often do not comprehensively cover liver cancer subtypes or include complete phasing of CT scans. We hypothesize that utilizing full-phase 3D CECT images, including the Plain, Arterial, Venous, and Delayed phases, can improve the diagnostic classification performance for liver cancer. To test this hypothesis, we have collected a large dataset from a single medical institution that includes 278 cases of liver cancer, featuring Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), and Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA), as well as CECT images from 83 non-liver cancer subjects. For each patient, we annotated the liver and lesion regions. This dataset, rich in liver cancer types and complete in CT phasing, facilitates the development and validation of diagnostic classification models and lesion segmentation models tailored to liver cancer CT imaging.The median age of participants was 59 years 51, 67, with 185 males (67.3% of the liver cancer group) . Each patient had complete 3D contrast-enhanced CT (CECT) data across the Plain, Arterial, Venous, and Delayed phases, stored as NIFTI files. A total of 50,560 slices containing lesions were collected, with a median lesion volume of 75.37 cm³ [26.70, 239.24] . The Python code for loading and processing the data can be found on GitHub (https://github.com/ljwa2323/PLC_CECT).

  4. f

    table_1_Liver Cancer Disparities in New York City: A Neighborhood View of...

    • frontiersin.figshare.com
    docx
    Updated May 30, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Geetanjali R. Kamath; Emanuela Taioli; Natalia N. Egorova; Josep M. Llovet; Ponni V. Perumalswami; Jeffrey J. Weiss; Myron Schwartz; Stanley Ewala; Nina A. Bickell (2023). table_1_Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors.docx [Dataset]. http://doi.org/10.3389/fonc.2018.00220.s001
    Explore at:
    docxAvailable download formats
    Dataset updated
    May 30, 2023
    Dataset provided by
    Frontiers
    Authors
    Geetanjali R. Kamath; Emanuela Taioli; Natalia N. Egorova; Josep M. Llovet; Ponni V. Perumalswami; Jeffrey J. Weiss; Myron Schwartz; Stanley Ewala; Nina A. Bickell
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Area covered
    New York
    Description

    IntroductionLiver cancer is the fastest increasing cancer in the United States and is one of the leading causes of cancer-related death in New York City (NYC), with wide disparities among neighborhoods. The purpose of this cross-sectional study was to describe liver cancer incidence by neighborhood and examine its association with risk factors. This information can inform preventive and treatment interventions.Materials and methodsPublicly available data were collected on adult NYC residents (n = 6,407,022). Age-adjusted data on liver and intrahepatic bile duct cancer came from the New York State Cancer Registry (1) (2007–2011 average annual incidence); and the NYC Vital Statistics Bureau (2015, mortality). Data on liver cancer risk factors (2012–2015) were sourced from the New York City Department of Health and Mental Hygiene: (1) Community Health Survey, (2) A1C registry, and (3) NYC Health Department Hepatitis surveillance data. They included prevalence of obesity, diabetes, diabetic control, alcohol-related hospitalizations or emergency department visits, hepatitis B and C rates, hepatitis B vaccine coverage, and injecting drug use.ResultsLiver cancer incidence in NYC was strongly associated with neighborhood poverty after adjusting for race/ethnicity (β = 0.0217, p = 0.013); and with infection risk scores (β = 0.0389, 95% CI = 0.0088–0.069, p = 0.011), particularly in the poorest neighborhoods (β = 0.1207, 95% CI = 0.0147–0.2267, p = 0.026). Some neighborhoods with high hepatitis rates do not have a proportionate number of hepatitis prevention services.ConclusionHigh liver cancer incidence is strongly associated with infection risk factors in NYC. There are gaps in hepatitis prevention services like syringe exchange and vaccination that should be addressed. The role of alcohol and metabolic risk factors on liver cancer in NYC warrants further study.

  5. Z

    Dataset related to article "Incidence and predictors of hepatocellular...

    • data.niaid.nih.gov
    Updated Jan 19, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    van den Berg, AP (2024). Dataset related to article "Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis" [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_10532882
    Explore at:
    Dataset updated
    Jan 19, 2024
    Dataset provided by
    Zachou, K
    Lytvyak, E
    Muratori, P
    Slooter, CD
    Beuers, U
    Macedo, G
    International Autoimmune Hepatitis Group
    de Boer, YS
    Aghemo, Alessio
    Carella, F
    Colapietro, D
    van den Berg, AP
    LLEO, Ana
    Robles, M
    Dalekos, GN
    Dutch AIH Study Group
    Di Zeo-Sánchez, DE
    Brouwer, JT
    Kuiken, SD
    van Hoek, B
    Maisonneuve, P
    Andrade, RJ
    van der Meer, AJ
    van den Brand, FF
    Verdonk, RC
    Montano-Loza, AJ
    Liberal, R
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    This record contains raw data related to article “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis"

    Abstract

    Background and aims: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors.

    Methods: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry. The assessed clinical outcomes were HCC development, liver transplantation, and death. Fine and Gray regression analysis stratified by centre was applied to determine the effects of individual covariates; the cumulative incidence of HCC was estimated using the competing risk method with death as a competing risk.

    Results: A total of 1,428 patients diagnosed with AIH from 1980 to 2020 from 22 eligible centres across Europe and Canada were included, with a median follow-up of 11.1 years (interquartile range 5.2-15.9). Two hundred and ninety-three (20.5%) patients had cirrhosis at diagnosis. During follow-up, 24 patients developed HCC (1.7%), an incidence rate of 1.44 cases/1,000 patient-years; the cumulative incidence of HCC increased over time (0.6% at 5 years, 0.9% at 10 years, 2.7% at 20 years, and 6.6% at 30 years of follow-up). Patients who developed cirrhosis during follow-up had a significantly higher incidence of HCC. The cumulative incidence of HCC was 2.6%, 4.6%, 5.6% and 6.6% at 5, 10, 15, and 20 years after the development of cirrhosis, respectively. Obesity (hazard ratio [HR] 2.94, p = 0.04), cirrhosis (HR 3.17, p = 0.01), and AIH/PSC variant syndrome (HR 5.18, p = 0.007) at baseline were independent risk factors for HCC development.

    Conclusions: HCC incidence in AIH is low even after cirrhosis development and is associated with risk factors including obesity, cirrhosis, and AIH/PSC variant syndrome.

    Impact and implications: The risk of developing hepatocellular carcinoma (HCC) in individuals with autoimmune hepatitis (AIH) seems to be lower than for other aetiologies of chronic liver disease. Yet, solid data for this specific patient group remain elusive, given that most of the existing evidence comes from small, single-centre studies. In our study, we found that HCC incidence in patients with AIH is low even after the onset of cirrhosis. Additionally, factors such as advanced age, obesity, cirrhosis, alcohol consumption, and the presence of the AIH/PSC variant syndrome at the time of AIH diagnosis are linked to a higher risk of HCC. Based on these findings, there seems to be merit in adopting a specialized HCC monitoring programme for patients with AIH based on their individual risk factors.

  6. f

    Supplementary Material for: The Burden and Trends of Primary Liver Cancer...

    • karger.figshare.com
    docx
    Updated Jun 2, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Lin L.; Yan L.; Liu Y.; Qu C.; Ni J.; Li H. (2023). Supplementary Material for: The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017 [Dataset]. http://doi.org/10.6084/m9.figshare.12696437.v1
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 2, 2023
    Dataset provided by
    Karger Publishers
    Authors
    Lin L.; Yan L.; Liu Y.; Qu C.; Ni J.; Li H.
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Background: Liver cancer is one of the leading causes of cancer-related deaths worldwide. The primary causes of liver cancer include hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol consumption, nonalcoholic fatty liver disease, and other factors. Aims: The objective of this study was to evaluate the global and sex-, age-, region-, country-, and etiology-related liver cancer burden, as well as the trends in liver cancer caused by different etiologies. Methods: The causes of liver cancer from 1990 to 2017, including global, regional, and national liver cancer incidence, mortality, and etiology, were collected from the Global Burden of Disease study 2017, and the time-dependent change in the trends of liver cancer burden was evaluated by annual percentage change. Results: The global liver cancer incidence and mortality have been increasing. There were 950,000 newly-diagnosed liver cancer cases and over 800,000 deaths in 2017, which is more than twice the numbers recorded in 1990. HBV and HCV are the major causes of liver cancer. HBV is the major risk factor of liver cancer in Asia, while HCV and alcohol abuse are the major risk factors in the high sociodemographic index and high human development index regions. The mean onset age and incidence of liver cancer with different etiologies have gradually increased in the past 30 years. Conclusions: The global incidence is still rising and the causes have national, regional, or population specificities. More targeted prevention strategies must be developed for the different etiologic types in order to reduce liver cancer burden.

  7. Deaths by cancer in the U.S. 1950-2022

    • statista.com
    • ai-chatbox.pro
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    John Elflein, Deaths by cancer in the U.S. 1950-2022 [Dataset]. https://www.statista.com/topics/1192/cancer-in-the-us/
    Explore at:
    Dataset provided by
    Statistahttp://statista.com/
    Authors
    John Elflein
    Area covered
    United States
    Description

    Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

  8. f

    Data Sheet 1_Global burden and international disparities in NASH-associated...

    • frontiersin.figshare.com
    pdf
    Updated Feb 14, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Qilong Nie; Yongwen Jiang; Mingyang Li; Qiuyan Liang; Xiaoai Mo; Tengyu Qiu; Qunfang Jiang; Kaizhou Huang; Youqing Xie; Ying Chen; Xiaojun Ma; Jianhong Li; Kaiping Jiang (2025). Data Sheet 1_Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990–2021) and future projections to 2045.pdf [Dataset]. http://doi.org/10.3389/fpubh.2025.1527328.s001
    Explore at:
    pdfAvailable download formats
    Dataset updated
    Feb 14, 2025
    Dataset provided by
    Frontiers
    Authors
    Qilong Nie; Yongwen Jiang; Mingyang Li; Qiuyan Liang; Xiaoai Mo; Tengyu Qiu; Qunfang Jiang; Kaizhou Huang; Youqing Xie; Ying Chen; Xiaojun Ma; Jianhong Li; Kaiping Jiang
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    BackgroundNASH-associated liver cancer (NALC) is a significant contributor to global cancer mortality, closely linked to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This study comprehensively examines the global burden of NALC from 1990 to 2021.MethodsThis study used data from the Global Burden of Disease (GBD) 2021 database to analyze NALC death and age-standardized death rates (ASDR) globally and regionally from 1990 to 2021. We applied Joinpoint regression analysis to assess temporal trends, calculating the annual percent change (APC) and average annual percent change (AAPC). Decomposition analysis was performed to break down mortality changes into contributions from population aging, growth, and epidemiological changes. A frontier analysis was used to evaluate the relationship between NALC burden and sociodemographic development using the Socio-Demographic Index (SDI). Prediction analysis of NALC deaths and ASDR from 2021 to 2045 were estimated using the Nordpred model.ResultsFrom 1990 to 2021, the global burden of NALC deaths increased significantly, with the ASDR rising from 0.38 per 100,000 in 1990 to 0.48 per 100,000 in 2021. Age-specific data in 2021 revealed that NALC deaths peaked in the 65–69 age group for men and 70–74 age group for women. Decomposition analysis indicated that population growth was the most significant contributor to the global NALC death toll, followed by population aging and epidemiological changes. Frontier analysis showed that countries like Mongolia and Gambia were farthest from the disease burden frontier, while Morocco and Ukraine were closest. Prediction analysis suggest a significant increase in NALC deaths by 2045 compared to 2021, with a larger rise in deaths among women.ConclusionThrough this study, a data-driven approach is provided to reduce the global disease burden of NALC. Essential data support for public health prevention strategies is offered, helping guide the development of targeted government interventions. Trends across global regions, countries, age groups, and genders have been analyzed, providing valuable insights for the formulation of evidence-based policies aimed at mitigating the impact of NALC worldwide.

  9. f

    DataSheet_1_Nonalcoholic fatty liver disease is specifically related to the...

    • frontiersin.figshare.com
    docx
    Updated Jun 21, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Somaya Albhaisi; Donna McClish; Le Kang; Tamas Gal; Arun J. Sanyal (2023). DataSheet_1_Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies.docx [Dataset]. http://doi.org/10.3389/fendo.2022.1037211.s001
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 21, 2023
    Dataset provided by
    Frontiers
    Authors
    Somaya Albhaisi; Donna McClish; Le Kang; Tamas Gal; Arun J. Sanyal
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    ObjectiveWe performed a matched cohort study among individuals with and without nonalcoholic fatty liver disease (NAFLD) to determine: 1) the incidence of cancers (extrahepatic and liver) and their spectrum and 2) if NAFLD increases the risk of extrahepatic cancers.MethodsThe NAFLD and non-NAFLD (control) cohorts were identified from electronic medical records via International Classification of Diseases (ICD) codes from a single center and followed from 2010 to 2019. Cohorts were matched 1:2 for age, sex, race, body mass index (BMI), and type 2 diabetes.ResultsA total of 1,412 subjects were included in the analyses. There were 477 individuals with NAFLD and 935 controls (median age, 52 years; women, 54%; white vs. black: 59% vs. 38%; median BMI, 30.4 kg/m2; type 2 diabetes, 34%). The cancer incidence (per 100,000 person-years) was 535 vs. 1,513 (NAFLD vs. control). Liver cancer incidence (per 100,000 person-years) was 89 in the NAFLD group vs. 0 in the control group, whereas the incidence of malignancy was higher across other types of cancer in the control group vs. in the NAFLD group.ConclusionsThe overall extrahepatic cancer risk in NAFLD is not increased above and beyond the risk from background risk factors such as age, race, sex, BMI, and type 2 diabetes.

  10. c

    Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver...

    • cancerimagingarchive.net
    • dev.cancerimagingarchive.net
    dicom, n/a
    Updated Feb 17, 2017
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    The Cancer Imaging Archive (2017). Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer [Dataset]. http://doi.org/10.7937/F2DB-8826
    Explore at:
    n/a, dicomAvailable download formats
    Dataset updated
    Feb 17, 2017
    Dataset authored and provided by
    The Cancer Imaging Archive
    License

    https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/

    Time period covered
    Oct 30, 2024
    Dataset funded by
    National Cancer Institutehttp://www.cancer.gov/
    Description

    https://www.cancerimagingarchive.net/wp-content/uploads/nctn-logo-300x108.png" alt="" width="300" height="108" />

    Demographic Summary of Available Imaging

    CharacteristicValue (N = 190)
    Age (months)Mean ± SD: 25.3 ± 29
    Median (IQR): 17 (10-30.2)
    Range: 0-189
    SexMale: 120 (63%)
    Female: 70 (37%)
    Race

    Not Available

    Ethnicity

    Not Available

    This collection contains data from the National Cancer Institute Clinical Trial NCT00980460, "Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer." It was sponsored by NCI's Children’s Oncology Group (COG) under study number AHEP0731. This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive.

    Trial Description

    Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary, liver transplant, are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.

    Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. The aim is to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. This multicentre, phase 3 trial was designed to test a risk-based treatment approach for children with hepatoblastoma, to diminish toxicity in low-risk patients, improve survival in intermediate-risk patients, and identify new agents that may be used in high-risk and recurrent patients. Patients were staged for risk classification using the Children’s Oncology Group staging guidelines before the initiation of chemotherapy, with stage IV indicating metastatic disease. Pretreatment extent of disease (PRETEXT) grouping also was performed at the time of diagnosis and with any subsequent abdominal computed tomography or magnetic resonance imaging and was used to guide the surgical management but was not used for risk classification. The response rate and outcome to the combination of vincristine and irinotecan administered in an upfront window to children newly diagnosed with high-risk hepatoblastoma was determined.

    For Low-Risk patients CT chest was used for metastatic tumor response assessment. Abdominal Ultrasound was obtained at baseline. For Intermediate- and High-Risk patients abdominal ultrasound, CT and/or MRI was used for primary tumor response assessment and CT chest for metastatic tumor response assessment.

    Trial Outcomes

    Results of the trial for Low-Risk patients have been reported in the following publication:

    Katzenstein, H. M., Langham, M. R., Malogolowkin, M. H., Krailo, M. D., Towbin, A. J., McCarville, M. B., Finegold, M. J., Ranganathan, S., Dunn, S., McGahren, E. D., Tiao, G. M., O’Neill, A. F., Qayed, M., Furman, W. L., Xia, C., Rodriguez-Galindo, C., & Meyers, R. L. (2019). Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children’s Oncology Group, multicentre, phase 3 trial. The Lancet Oncology, 20(5), 719–727. DOI: https://doi.org/10.1016/s1470-2045(18)30895-7. Epub 2019 Apr 8. Erratum in: Lancet Oncol. 2019 May;20(5):e243. PMID: 30975630; PMCID: PMC6499702. Epub 2019 Apr 8. Erratum in: Lancet Oncol. 2019 May;20(5):e243. PMID: 30975630; PMCID: PMC6499702.

  11. f

    Cumulative hepatocellular carcinoma incidence (%) in subgroups by age, sex,...

    • plos.figshare.com
    xls
    Updated Nov 8, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Rongtao Lai; Scott Barnett; Xinrong Zhang; Leslie Yeeman Kam; Ramsey Cheung; Qing Xie; Mindie H. Nguyen (2024). Cumulative hepatocellular carcinoma incidence (%) in subgroups by age, sex, cirrhosis, diabetes mellitus, or other non-hepatic events. [Dataset]. http://doi.org/10.1371/journal.pmed.1004479.t002
    Explore at:
    xlsAvailable download formats
    Dataset updated
    Nov 8, 2024
    Dataset provided by
    PLOS Medicine
    Authors
    Rongtao Lai; Scott Barnett; Xinrong Zhang; Leslie Yeeman Kam; Ramsey Cheung; Qing Xie; Mindie H. Nguyen
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Cumulative hepatocellular carcinoma incidence (%) in subgroups by age, sex, cirrhosis, diabetes mellitus, or other non-hepatic events.

  12. f

    Gp78, an E3 Ubiquitin Ligase Acts as a Gatekeeper Suppressing Nonalcoholic...

    • plos.figshare.com
    tiff
    Updated May 31, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Tianpeng Zhang; Dhong Hyo Kho; Ying Wang; Yosuke Harazono; Kosei Nakajima; Youming Xie; Avraham Raz (2023). Gp78, an E3 Ubiquitin Ligase Acts as a Gatekeeper Suppressing Nonalcoholic Steatohepatitis (NASH) and Liver Cancer [Dataset]. http://doi.org/10.1371/journal.pone.0118448
    Explore at:
    tiffAvailable download formats
    Dataset updated
    May 31, 2023
    Dataset provided by
    PLOS ONE
    Authors
    Tianpeng Zhang; Dhong Hyo Kho; Ying Wang; Yosuke Harazono; Kosei Nakajima; Youming Xie; Avraham Raz
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Nonalcoholic steatohepatitis (NASH) is related to metabolic dysregulation and the perturbation of endoplasmic reticulum (ER) homeostasis that frequently develops into hepatocellular carcinoma (HCC). Gp78 is E3 ligase, which regulates endoplasmic reticulum-associated degradation (ERAD) by ubiquitinylation of misfolded ER proteins. Here, we report that upon ageing (12 months), gp78-/- mice developed obesity, recapitulating age-related human NASH. Liver histology of gp78-/- mice revealed typical steatosis, hepatic inflammation and fibrosis, followed by progression to hepatocellular tumors. Acute ER stress revealed that loss of gp78 results in up regulation of unfolded protein response (UPR) pathways and SREBP-1 regulating de novo lipogenesis, responsible for fatty liver. Tissue array of human hepatocellular carcinoma (HCC) demonstrated that the expression of gp78 was inversely correlated with clinical grades of cancer. Here, we have described the generation of the first preclinical experimental model system which spontaneously develops age-related NASH and HCC, linking ERAD to hepatosteatosis, cirrhosis, and cancer. It suggests that gp78 is a regulator of normal liver homeostasis and a tumor suppressor in human liver.

  13. Z

    Raw Data for the article: How important is the role of iterative liver...

    • data.niaid.nih.gov
    • zenodo.org
    Updated Feb 11, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Duilio Pagano (2023). Raw Data for the article: How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation? [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_7628700
    Explore at:
    Dataset updated
    Feb 11, 2023
    Dataset authored and provided by
    Duilio Pagano
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Introduction: Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA).

    Methods: We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them.

    Results: There were 557 HCC patients treated with a first-line approach of LR and/or LRTs (n = 335) or LT (n = 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47, p = 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94, p = 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94, p < 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12, p = 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40, p = 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0, p = 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36, p = 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99, p = 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00, p = 0.051).

    Conclusion: The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival.

  14. Z

    Dataset related to article "Liver metastases from colorectal cancer:...

    • data.niaid.nih.gov
    • zenodo.org
    Updated Jul 22, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Di Brina, Lucia (2024). Dataset related to article "Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation" [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_3406568
    Explore at:
    Dataset updated
    Jul 22, 2024
    Dataset provided by
    Franzese, Ciro
    Vigano', Luca
    Navarria, Pierina
    Solbiati, Luigi Alessandro
    Tomatis, Stefano Maria
    Reggiori, Giacomo
    Poretti, Dario
    Pedicini, Vittorio
    Di Brina, Lucia
    Clerici, Elena
    Torzilli, Guido
    Comito, Tiziana
    Scorsetti, Marta
    Description

    This record contains raw data related to article "Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation"

    PURPOSE:

    The study aim was to compare the disease control in two groups of patients affected by liver metastases from CRC treated with microwave ablation (MWA) or stereotactic body radiation therapy (SBRT).

    METHODS:

    We extracted data of patients treated between 2009 and 2016. Inclusion criteria were: (1) maximum diameter of the liver lesions less than 4 cm; (2) no more than three liver lesions; (3) no evidence of progressive or untreated gross disease outside the liver; (4) adequate liver function; (5) no concurrent chemotherapy; (6) minimum age of 18. Tumour response was classified according to EORTC-RECIST criteria. Aim of the present study was to evaluate freedom from local progression (FFLP). To reduce indication bias, an inverse probability of treatment weighting was used to estimate treatment effect.

    RESULTS:

    A total of 135 patients with 214 lesions were included in the analysis. Median follow-up time was 24.5 months (range 2.4-95.8). The 1-year freedom from local progression (FFLP) was 88% (95%CI 80-92). In the SBRT group, FFLP was statistically longer than MWA group (p = 0.0214); the 1-year FFLP was 91% (95% CI 81-95) in SBRT group and 84% (95% CI 0.72-0.91) in MWA group. Patients treated with SBRT showed a reduce risk of local relapse compared to MWA (adjusted HR 0.31; 95%CI 0.13-0.70, p = 0.005). As expected, analogous result obtained in the inverse probability weighting analysis (HR 0.38; 95%CI 0.18-0.80; p = 0.011).

    CONCLUSION:

    In conclusion, there seems to be an advantage of SBRT compared to MWA in treating CRC liver metastases, particularly for lesions bigger than 30 mm.

  15. Data from: Annexes to the risk assessment of aflatoxins in food

    • zenodo.org
    • data.niaid.nih.gov
    • +1more
    Updated Apr 23, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    EFSA CONTAM Panel; Schrenk Dieter; Margherita Bignami; Laurent Bodin; James Kevin Chipman; Jesús del Mazo; Bettina Grasl-Kraupp; Christer Hogstrand; Laurentius (Ron) Hoogenboom; Jean-Charles Leblanc; Carlo Stefano Nebbia; Elsa Nielsen; Evanghelia Ntzani; Annette Petersen; Salomon Sand; Tanja Schwertdle; Christiane Vleminckx; Doris Marko; Isabelle P Oswald; Aldert Piersma; Michael Routledge; Josef Schlatter; Katleen Baert; Petra Gergelova; Heather Wallace; EFSA CONTAM Panel; Schrenk Dieter; Margherita Bignami; Laurent Bodin; James Kevin Chipman; Jesús del Mazo; Bettina Grasl-Kraupp; Christer Hogstrand; Laurentius (Ron) Hoogenboom; Jean-Charles Leblanc; Carlo Stefano Nebbia; Elsa Nielsen; Evanghelia Ntzani; Annette Petersen; Salomon Sand; Tanja Schwertdle; Christiane Vleminckx; Doris Marko; Isabelle P Oswald; Aldert Piersma; Michael Routledge; Josef Schlatter; Katleen Baert; Petra Gergelova; Heather Wallace (2020). Annexes to the risk assessment of aflatoxins in food [Dataset]. http://doi.org/10.5281/zenodo.3607186
    Explore at:
    Dataset updated
    Apr 23, 2020
    Dataset provided by
    Zenodohttp://zenodo.org/
    Authors
    EFSA CONTAM Panel; Schrenk Dieter; Margherita Bignami; Laurent Bodin; James Kevin Chipman; Jesús del Mazo; Bettina Grasl-Kraupp; Christer Hogstrand; Laurentius (Ron) Hoogenboom; Jean-Charles Leblanc; Carlo Stefano Nebbia; Elsa Nielsen; Evanghelia Ntzani; Annette Petersen; Salomon Sand; Tanja Schwertdle; Christiane Vleminckx; Doris Marko; Isabelle P Oswald; Aldert Piersma; Michael Routledge; Josef Schlatter; Katleen Baert; Petra Gergelova; Heather Wallace; EFSA CONTAM Panel; Schrenk Dieter; Margherita Bignami; Laurent Bodin; James Kevin Chipman; Jesús del Mazo; Bettina Grasl-Kraupp; Christer Hogstrand; Laurentius (Ron) Hoogenboom; Jean-Charles Leblanc; Carlo Stefano Nebbia; Elsa Nielsen; Evanghelia Ntzani; Annette Petersen; Salomon Sand; Tanja Schwertdle; Christiane Vleminckx; Doris Marko; Isabelle P Oswald; Aldert Piersma; Michael Routledge; Josef Schlatter; Katleen Baert; Petra Gergelova; Heather Wallace
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    The annexes A to E to the Scientific Opinion on Aflatoxins in Food included in the upload are excel files as follows:

    • Annex A: Dietary surveys per country and age group available in the EFSA Comprehensive Database, considered in the exposure assessment
    • Annex B: Occurrence data on aflatoxins
    • Annex C: Proportion of left-censored data and the mean concentrations of the quantified analytical results of AFB1 for pistachios, hazelnuts, peanuts, other nuts and dried figs
    • Annex D: AFB1 and AFM1 concentrations reported for organic farming and conventional farming in selected food categories
    • Annex E: Mean and high chronic dietary exposure to aflatoxins per survey and the contribution of different food groups to the dietary exposure

  16. Z

    Dataset related to article "Stereotactic Body Radiation Therapy for Lung and...

    • data.niaid.nih.gov
    • zenodo.org
    Updated Oct 24, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Franceschini, Davide (2023). Dataset related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial" [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_10036165
    Explore at:
    Dataset updated
    Oct 24, 2023
    Dataset provided by
    Di Cristina, Luciana
    Spoto, Ruggero
    Scorsetti, Marta
    Dominici, Luca
    Lo Faro, Lorenzo
    Vernier, Veronica
    Marini, Beatrice
    Stefanini, Sara
    Franceschini, Davide
    Marzo, Marco
    Di Gallo, Anna
    franzese, ciro
    comito, tiziana
    Description

    This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial" Abstract Aims: We report the mature toxicity data of a phase II non-randomized trial on the use of SBRT for lung and liver oligometastases. Methods: Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions. Inclusion criteria were: age > 18 years, ECOG 0-2, diagnosis of breast cancer, less than five lung/liver lesions (with a maximum diameter <5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. Various dose-fractionation schedules were used. Then, a 4D-CT scan and FDG-CTPET were acquired for simulation and fused for target definition. Results: From 2015 to 2021, 64 patients and a total of 90 lesions were irradiated. Treatment was well tolerated, with no G 3-4 toxicities. No grade ≥3 toxicities were registered and the coprimary endpoint of the study was met. Median follow-up was 19.4 months (range 2.6-73.1). Conclusions: The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.

  17. Z

    Raw Data for the article: ERAS Protocol for Perioperative Care of Patients...

    • data.niaid.nih.gov
    Updated Feb 24, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Gruttadauria Salvatore (2022). Raw Data for the article: ERAS Protocol for Perioperative Care of Patients Treated with Laparoscopic Nonanatomic Liver Resection for Hepatocellular Carcinoma: The ISMETT Experience [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_4633525
    Explore at:
    Dataset updated
    Feb 24, 2022
    Dataset provided by
    Pagano Duilio
    Gruttadauria Salvatore
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Background: Liver resection (LR) remains the best therapeutic option for patients with early-stage hepatocellular carcinoma (HCC) with preserved hepatic function and who are not eligible for liver transplantation. After its inception, the enhanced recovery after surgery (ERAS) protocol was widely used for treating patients with liver cancer, although there are still no clear indications for improving upon it in both open and laparoscopic surgery.

    Objective: This study aims to describe our institute's experience in the application of the ERAS protocol in a cohort of HCC patients, and to explore possible factors that could have an impact on postoperative outcomes.

    Materials and Methods: We retrospectively analyzed our experience with LR performed from September 2017 to January 2020 in patients treated with ERAS protocol, focusing on describing impact on postoperative nutrition, analgesic requirements, and length of hospitalization. Demographics, operative factors, and postoperative complications of patients were reviewed.

    Results: During the study period, 89 HCC patients were eligible for LR, and 75% of patients presented with liver cirrhosis. The most prevalent among etiologic factors was hepatitis C virus infection (53 patients out of 89, 60%), followed by nonalcoholic steatohepatitis (18 patients, 20%). The median age was 70 years. Liver cirrhosis did not have an impact on postoperative course of patients. Patients who underwent laparoscopic surgery and nonanatomic LR experienced low complication rates, shorter length of stay, and shorter time of intravenous analgesic requirements.

    Conclusions: Continual refinement with ERAS protocol for treating HCC patients based on perioperative counseling and surgical decision-making is crucial to guarantee low complication rates, and reduce patient morbidity and time for recovery.

  18. f

    DataSheet_1_The 20 years transition of clinical characteristics and...

    • frontiersin.figshare.com
    docx
    Updated Jun 20, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Yezhou Ding; Mingyang Feng; Di Ma; Gangde Zhao; Xiaolin Wang; Baoyan An; Yumin Xu; Shike Lou; Lanyi Lin; Qing Xie; Kehui Liu; Shisan Bao; Hui Wang (2023). DataSheet_1_The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China.docx [Dataset]. http://doi.org/10.3389/fonc.2023.1109980.s001
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 20, 2023
    Dataset provided by
    Frontiers
    Authors
    Yezhou Ding; Mingyang Feng; Di Ma; Gangde Zhao; Xiaolin Wang; Baoyan An; Yumin Xu; Shike Lou; Lanyi Lin; Qing Xie; Kehui Liu; Shisan Bao; Hui Wang
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    BackgroundThe clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated.MethodsIt was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients.ResultsThe average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P

  19. O

    2020 Non-Communicable (Chronic) Diseases

    • data.sandiegocounty.gov
    application/rdfxml +5
    Updated Apr 25, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    County of San Diego (2023). 2020 Non-Communicable (Chronic) Diseases [Dataset]. https://data.sandiegocounty.gov/w/cn4i-qb8f/by4r-nr9x?cur=7DcpiQYR6yL&from=7au2JJ4w89D
    Explore at:
    application/rssxml, csv, application/rdfxml, xml, tsv, jsonAvailable download formats
    Dataset updated
    Apr 25, 2023
    Dataset authored and provided by
    County of San Diego
    License

    U.S. Government Workshttps://www.usa.gov/government-works
    License information was derived automatically

    Description

    Data by medical encounter for the following conditions by age, race/ethnicity, and gender:

    Acute Myocardial Infarction (AMI)
    Asthma
    Bladder Cancer
    Brain Cancer
    Coronary Heart Disease (CHD)
    Colorectal Cancer
    Chronic Obstructive Pulmonary Disease (COPD)/Chronic Lower Respiratory Diseases
    Diabetes
    Female Breast Cancer
    Female Reproductive Cancer
    Heart Failure
    Hyperlipidemia (High Blood Cholesterol)
    Kidney Cancer
    Leukemia
    Liver Cancer Lung Cancer Lupus and Connective Tissue Disorders
    Melanoma of the Skin
    Non-Hodgkin's Lymphoma
    Non-melanoma Skin Cancer
    Overall Cancer
    Overall Heart Disease
    Overall Hypertensive Diseases
    Pancreatic Cancer
    Prostate Cancer Stroke
    Thyroid Cancer

    Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.
    Blank Cells: Rates not calculated for fewer than 11 events. Rates not calculated in cases where zip code is unknown. Geography not reported where there are no cases reported in a given year. SES: Is the median household income by SRA community. Data for SRAs only.
    *The COVID-19 pandemic was associated with increases in all-cause mortality. COVID-19 deaths have affected the patterns of mortality including those of Non-Communicable conditions.

    Data sources: California Department of Public Health, Center for Health Statistics, Office of Health Information and Research, Vital Records Business Intelligence System (VRBIS). California Department of Health Care Access and Information (HCAI), Emergency Department Database and Patient Discharge Database, 2020. SANDAG Population Estimates, 2020 (vintage: 09/2022). Population estimates were derived using the 2010 Census and data should be considered preliminary. Prepared by: County of San Diego, Health and Human Services Agency, Public Health Services, Community Health Statistics Unit, February 2023.

  20. Number of liver transplants performed in the U.S. as of 2024, by state

    • statista.com
    Updated May 22, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Number of liver transplants performed in the U.S. as of 2024, by state [Dataset]. https://www.statista.com/statistics/954207/us-liver-transplants-by-state/
    Explore at:
    Dataset updated
    May 22, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    2024
    Area covered
    United States
    Description

    In 2024, California had the highest number of liver transplants performed among all U.S. states. That year, there were around 1,243 liver transplants performed in California. The state with the second-highest number of liver transplants was Texas. Liver transplants are the second most common transplant in the United States, behind kidney transplants. Liver transplants in the United States In 2023, there were just over 10,660 liver transplants carried out in the United States. Most liver transplants in the U.S. are among adults aged 50 to 64 years, with this age group accounting for around 43 percent of all liver transplants. The current need for liver transplants exceeds availability, with over nine thousand people in the United States waiting to receive a liver transplant. Liver transplantation is a treatment option for those suffering from end-stage chronic liver disease, in which the liver is damaged beyond repair. Liver disease End-stage chronic liver disease, or liver failure, has various causes including cirrhosis, hepatitis B and C, and liver cancer. Around half of all deaths in the United States caused by liver cirrhosis are related to alcohol use. Liver cirrhosis is scarring of the liver because of long-term damage. The death rate due to alcohol-related cirrhosis in the United States has increased over the past couple decades. Men are much more likely to die from liver cirrhosis than women.

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Statista (2024). Rate of liver cancer diagnoses in the U.S. in 2021, by age [Dataset]. https://www.statista.com/statistics/951914/new-liver-cancer-cases-rate-by-age/
Organization logo

Rate of liver cancer diagnoses in the U.S. in 2021, by age

Explore at:
Dataset updated
Jul 9, 2024
Dataset authored and provided by
Statistahttp://statista.com/
Time period covered
2021
Area covered
United States
Description

The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

Search
Clear search
Close search
Google apps
Main menu